Analyst Ami Fadia of Needham maintained a Buy rating on Harmony Biosciences Holdings, retaining the price target of $49.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Ami Fadia has given her Buy rating due to a combination of factors that reflect both current performance and future potential. Despite Harmony Biosciences Holdings reporting slightly lower-than-expected sales and earnings per share for the second quarter of 2025, the company showed positive signs with an increase in the average number of patients on Wakix therapy. This growth in patient numbers indicates a strong demand for their product, which is a positive indicator for future revenue growth.
Moreover, the management’s reaffirmation of their full-year revenue guidance suggests confidence in meeting their financial targets. Additionally, the company’s pipeline development remains on track, with significant milestones expected, such as the initiation of the Phase 3 study for ZYN-002 in the 22q deletion syndrome and the anticipated topline data for ZYN-002 Phase 3 RECONNECT study. These developments highlight the company’s potential for future growth, supporting the Buy rating.
In another report released yesterday, Mizuho Securities also maintained a Buy rating on the stock with a $48.00 price target.